Wednesday: What’s Hot on CanLII
Each Wednesday we tell you which three English-language cases and which French-language case have been the most viewed* on CanLII and we give you a small sense of what the cases are about.
For this last week:
- Price v. H. Lundbeck A/S, 2018 ONSC 4333 (CanLII)
Approximately three and a half years ago, pursuant to the Class Proceedings Act, 1992, [Plaintiff] commenced a proposed class action against H. Lundbeck A/S and Lundbeck Canada Inc. (collectively “Lundbeck”), which are pharmaceutical companies that manufacture the drug “citalopram,” under the brand name Celexa®.
[2] Citalopram is an SSRI (selective serotonin reuptake inhibitor) indicated . . . [more]


